Resona Asset Management Co. Ltd. Buys 97,226 Shares of Charles River Laboratories International, Inc. $CRL

Charles River Laboratories International logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Resona Asset Management increased its Charles River Laboratories stake by 13,674.5%, buying 97,226 shares in the third quarter to hold 97,937 shares worth about $28.9 million. Other institutional investors also added shares; institutions own 98.91% of the stock.
  • Charles River reported quarterly EPS of $3.09 and revenue of $982.73 million, exceeding analyst estimates, although revenue declined 2.2% year over year.
  • Analyst sentiment was broadly positive, with 12 Buy, three Hold, and one Sell ratings. Meanwhile, company insiders sold 60,740 shares worth about $19.5 million over the quarter.
  • Interested in Charles River Laboratories International? Here are five stocks we like better.

Resona Asset Management Co. Ltd. boosted its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 13,674.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 97,937 shares of the medical research company's stock after purchasing an additional 97,226 shares during the quarter. Resona Asset Management Co. Ltd. owned approximately 0.20% of Charles River Laboratories International worth $28,892,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of CRL. Bank of America Corp DE grew its position in shares of Charles River Laboratories International by 5.0% in the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company's stock worth $195,792,000 after buying an additional 54,500 shares during the last quarter. Aberdeen Group plc lifted its position in Charles River Laboratories International by 483.6% during the third quarter. Aberdeen Group plc now owns 792,576 shares of the medical research company's stock valued at $233,818,000 after acquiring an additional 656,777 shares during the last quarter. Amundi lifted its position in Charles River Laboratories International by 175.2% during the first quarter. Amundi now owns 773,315 shares of the medical research company's stock valued at $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Charles River Laboratories International by 457.3% during the third quarter. Russell Investments Group Ltd. now owns 436,055 shares of the medical research company's stock valued at $128,641,000 after acquiring an additional 357,817 shares during the last quarter. Finally, Danske Bank A S boosted its stake in Charles River Laboratories International by 308,855.0% in the third quarter. Danske Bank A S now owns 308,955 shares of the medical research company's stock valued at $91,145,000 after acquiring an additional 308,855 shares in the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director James C. Foster sold 24,042 shares of Charles River Laboratories International stock in a transaction on Thursday, October 22nd. The shares were sold at an average price of $350.00, for a total transaction of $8,414,700.00. Following the completion of the sale, the director directly owned 31,596 shares in the company, valued at approximately $11,058,600. The trade was a 43.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of the business's stock in a transaction on Wednesday, October 21st. The shares were sold at an average price of $344.41, for a total transaction of $742,547.96. Following the sale, the executive vice president directly owned 4,807 shares in the company, valued at $1,655,578.87. This trade represents a 30.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 60,740 shares of company stock valued at $19,528,128 over the last quarter. Insiders own 1.30% of the company's stock.

Charles River Laboratories International Stock Performance

Shares of Charles River Laboratories International stock opened at $314.29 on Friday. The company has a 50 day moving average price of $316.09 and a 200 day moving average price of $231.19. The firm has a market capitalization of $15.06 billion, a P/E ratio of 345.37, a PEG ratio of 2.84 and a beta of 1.36. The company has a quick ratio of 1.12, a current ratio of 1.41 and a debt-to-equity ratio of 0.76. Charles River Laboratories International, Inc. has a 52 week low of $146.20 and a 52 week high of $379.63.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, November 4th. The medical research company reported $3.09 earnings per share for the quarter, topping the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a net margin of 1.01% and a return on equity of 16.95%. The company had revenue of $982.73 million for the quarter, compared to the consensus estimate of $960.36 million. During the same quarter in the previous year, the firm earned $2.43 EPS. Charles River Laboratories International's revenue was down 2.2% compared to the same quarter last year. Sell-side analysts expect that Charles River Laboratories International, Inc. will post 11.45 EPS for the current year.

Analyst Upgrades and Downgrades

CRL has been the topic of several analyst reports. Wall Street Zen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Saturday, November 7th. UBS Group increased their price objective on Charles River Laboratories International from $357.00 to $387.00 and gave the company a "buy" rating in a report on Thursday, November 5th. Deutsche Bank raised their price objective on Charles River Laboratories International from $300.00 to $320.00 and gave the stock a "buy" rating in a research report on Friday, September 25th. TD Cowen restated a "buy" rating and set a $388.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, November 11th. Finally, Royal Bank Of Canada boosted their target price on Charles River Laboratories International from $322.00 to $352.00 and gave the stock an "outperform" rating in a research note on Thursday, November 5th. Twelve analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Charles River Laboratories International has an average rating of "Moderate Buy" and an average price target of $311.67.

Check Out Our Latest Research Report on CRL

About Charles River Laboratories International

(Free Report)

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company's offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

See Also

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Charles River Laboratories International Right Now?

Before you consider Charles River Laboratories International, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Charles River Laboratories International wasn't on the list.

While Charles River Laboratories International currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines